FDA Clearance Tracker · P940035-S002
MATRITECH NMP22 TEST KIT
Last checked: Nov 20, 2026Latest source record: Jan 18, 2000 (this decision)Source: openFDAMethods & limitations
Decided
Jan 18, 2000
Approved
Time to decision
179 days
Received Jul 23, 1999. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P940035-S002
- Device name
- MATRITECH NMP22 TEST KIT
- Applicant
- Abbott Diagnostics Scarborough, Inc.
- Applicant location
- Scarborough, ME
- Received
- Jul 23, 1999
- Decided
- Jan 18, 2000
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P940035
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
The device is used as an aid 1)in the diagnosis of persons with symptoms or risk factors for transitional cell cancer (TCC) of the bladder (cut-off >= 7.5U/ml) in conjunction with and not in lieu of current standard diagnostic procedures and 2) in the management of patients with transitional cell carcinoma of the bladder, after surgical treatment to identify those patients with occult or rapidly recurring TCC (cut-off >10U/ml).
Source documents
Other decisions for Abbott Diagnostics Scarborough, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262747 · Decided Aug 31, 2026 · 28 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.